VEGFA and non-small cell lung carcinoma: The vascular endothelial growth factor (VEGF)-targeting antibody bevacizumab, for example, confers less benefit to females with non-small cell lung cancer (NSCLC) undergoing chemotherapy compared to males, demonstrating efficacy in a sex- and dose-dependent manner [44].